Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

Wyświetl całą dokumentację

O-024

Supelco

Olanzapine solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C17H20N4S
Numer CAS:
132539-06-1
Masa cząsteczkowa:
312.43
Numer WE:
200-835-2
Kod UNSPSC:
41116107
NACRES:
NA.24

klasa czystości

certified reference material

Poziom jakości

300

Formularz

liquid

Właściwości

Snap-N-Spike®/Snap-N-Shoot®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

stężenie

1.0 mg/mL in acetonitrile

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

clinical testing

Format

single component solution

temp. przechowywania

−20°C

ciąg SMILES

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

Klucz InChI

KVWDHTXUZHCGIO-UHFFFAOYSA-N

informacje o genach

human ... DRD2(1813) , DRD3(1814) , DRD4(1815) , HTR2A(3356) , HTR2C(3358)

Powiązane kategorie

Opis ogólny

An analytical reference standard for use in LC/MS or GC/MS applications including clinical toxicology analysis or therapeutic drug monitoring. Marketed under the trade name Zyprexa®, olanzapine is an atypical antipsychotic drug used in the treatment of schizophrenia and bipolar disorder.

Zastosowanie

  • Metabolic impact of Olanzapine in bipolar disorder: A network meta-analysis of randomized-controlled trials assessed the metabolic effects of antipsychotics and mood stabilizers, including Olanzapine, in patients with bipolar disorder, providing insights into its pharmacodynamic properties and implications for treatment optimization (Kong et al., 2024).
  • Machine learning in schizophrenia research: Olanzapine′s effectiveness was evaluated through a systematic review employing machine learning to predict violent behaviors in schizophrenia spectrum disorders. This study underscores the relevance of antipsychotic treatment profiling in enhancing patient-specific therapeutic strategies (Delvecchio et al., 2024).
  • Solubility and bioavailability enhancement: Research focused on the evaluation of polymeric matrices for loading poorly water-soluble drugs, like Olanzapine, into mesoporous silica. This study advances the development of more effective and bioavailable oral liquid formulations of Olanzapine (Barmpalexis et al., 2024).

Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zyprexa is a registered trademark of Eli Lilly and Co.
Ta strona może zawierać tekst przetłumaczony maszynowo.

Piktogramy

FlameExclamation mark
GHS02,GHS07

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H225,H302 + H312 + H332,H319

Klasyfikacja zagrożeń

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

35.6 °F - closed cup

Temperatura zapłonu (°C)

2 °C - closed cup

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 9

1 of 9

Aripiprazole solution 1.0 mg/mL (50:50 Methanol/Water with 1% 1N HCl), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-119

Aripiprazole solution

Chlorpromazine hydrochloride solution 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-904

Chlorpromazine hydrochloride solution

Pregabalin solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-066

Pregabalin solution

Clozapine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-059

Clozapine solution

Nitrazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

N-906

Nitrazepam solution

Risperidone-D4 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

R-013

Risperidone-D4 solution

Olanzapine ≥98% (HPLC)

Sigma-Aldrich

O1141

Olanzapine

Olanzapine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1825

Olanzapine

Olanzapine European Pharmacopoeia (EP) Reference Standard

Y0001370

Olanzapine

Jean A Milstein et al.
PloS one, 8(2), e57308-e57308 (2013-02-26)
Antipsychotic drugs are increasingly used in children and adolescents to treat a variety of psychiatric disorders. However, little is known about the long-term effects of early life antipsychotic drug treatment. Most antipsychotic drugs are potent antagonists or partial agonists of
Heating under high-frequency inductive conditions: application to the continuous synthesis of the neurolepticum olanzapine (Zyprexa).
Jan Hartwig et al.
Angewandte Chemie (International ed. in English), 52(37), 9813-9817 (2013-07-31)
Joseph P McEvoy et al.
The Journal of clinical psychiatry, 74(2), 170-179 (2013-03-12)
To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2
Stephen M Stahl et al.
The Journal of clinical psychiatry, 74(5), 507-515 (2013-04-02)
The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome. Patients who completed a 6-week, double-blind
A B Petersen et al.
Clinical toxicology (Philadelphia, Pa.), 52(1), 39-43 (2013-12-10)
In 2012, Danish psychiatrist raised concerns regarding the use of high-dose olanzapine in the treatment of patients. The present study was part of an audit carried out by the Mental Health Services of the Capitol Region of Denmark regarding this
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej